Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
0 hedge funds and large institutions have $0 invested in Avenue Therapeutics, Inc. Common Stock in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 7 closing their positions.
100% less funds holding
Funds holding: 7 → 0 (-7)
100% less capital invested
Capital invested by funds: $385K → $0 (-$385K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$280K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$82.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$15.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.19K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IC
1
Ikarian Capital
Dallas,
Texas
| – | -$280K | -140,000 | Closed |
|
|
BFM
2
Boothbay Fund Management
New York
| – | -$82.2K | -41,089 | Closed |
|
|
3
UBS Group
Zurich,
Switzerland
| – | -$15.8K | -7,920 | Closed |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| – | -$6.19K | -3,096 | Closed |
|
|
5
Wells Fargo
San Francisco,
California
| – | -$1K | -500 | Closed |
|
6
Bank of America
Charlotte,
North Carolina
| – | -$28 | -14 | Closed |
|
|
SS
7
SBI Securities
Tokyo,
Japan
| – | -$18 | -9 | Closed |
|
ATXI Hedge Fund Activity: Q1 2025 in Review
0 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q1 2025, worth a combined $0 — down 100% from $385K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ATXI and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Ikarian Capital, exiting entirely with an estimated $280K sold.
- 0 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q1 2025, down from 7 in Q4 2024.
- Funds reported $0 of Avenue Therapeutics, Inc. Common Stock stock for Q1 2025, down 100% quarter-over-quarter.
- 0 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q1 2025 and 7 closed out, a net change of -7 holders.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q1 2025 was Ikarian Capital, an estimated $280K sold.
Based on aggregated 13F filings for Q1 2025.